Biological and protective properties of immune sera directed to the influenza virus neuraminidase

Journal of Virology

Volumn 89, Issue 3, 2015, Pages 1550-1563

  Halbherr, Stefan J ^a   Ludersdorfer, Thomas H ^a   Ricklin, Meret ^a   Locher, Samira ^a   Rentsch, Marianne Berger ^a   Summerfield, Artur ^a   Zimmer, Gert ^a  

^a INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; INFLUENZA VACCINE; VIRUS SIALIDASE; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; HEMAGGLUTINATION INHIBITION TEST; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA VACCINATION; INHIBITION KINETICS; MDCK CELL LINE; NONHUMAN; PROTEIN EXPRESSION; REPLICON; VIRUS ATTACHMENT; VIRUS HEMAGGLUTINATION; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS RELEASE; VIRUS SHEDDING; VIRUS TRANSMISSION; ANIMAL; CELL LINE; CHICKEN; DOG; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; PIG; VIRUS ENTRY;

AVIAN INFLUENZA VIRUS; GALLUS GALLUS; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CHICKENS; DOGS; IMMUNE SERA; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; NEURAMINIDASE; SWINE; VIRAL PROTEINS; VIRUS INTERNALIZATION; VIRUS RELEASE; VIRUS SHEDDING;

EID: 84921502751     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02949-14     Document Type: Article

References (79)

1. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
2. Lotan R, Skutelsky E, Danon D, Sharon N. 1975. The purification, composition, and specificity of the anti-T lectin from peanut (Arachis hypogaea). J Biol Chem 250:8518-8523.
3. Xu X, Cox NJ, Bender CA, Regnery HL, Shaw MW. 1996. Genetic variation in neuraminidase genes of influenza A (H3N2) viruses. Virology 224:175-183. http://dx.doi.org/10.1006/viro.1996.0519.
4. Luther P, Bergmann KC, Oxford JS. 1984. An investigation of antigenic drift of neuraminidases of influenza A (H1N1) viruses. J Hyg 92:223-229. http://dx.doi.org/10.1017/S002217240006424X.
5. Kilbourne ED, Johansson BE, Grajower B. 1990. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci U S A 87:786-790. http://dx.doi.org/10.1073/pnas.87.2.786.
6. Sandbulte MR, Westgeest KB, Gao J, Xu X, Klimov AI, Russell CA, Burke DF, Smith DJ, Fouchier RA, Eichelberger MC. 2011. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A 108:20748-20753. http://dx.doi.org/10.1073/pnas.1113801108.
7. Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen LM, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney PJ, Gilbert AT, Chang J, Guo Z, Davis CT, Paulson JC, Stevens J, Rupprecht CE, Holmes EC, Wilson IA, Donis RO. 2013. New world bats harbor diverse influenza A viruses. PLoS Pathog 9:e1003657. http://dx.doi.org/10.1371/journal.ppat.1003657.
8. Air GM. 2012. Influenza neuraminidase. Influenza Other Respir Viruses 6:245-256. http://dx.doi.org/10.1111/j.1750-2659.2011.00304.x.
9. Palese P, Tobita K, Ueda M, Compans RW. 1974. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397-410. http://dx.doi.org/10.1016/0042-6822(74)90276-1.
10. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665-12667. http://dx.doi.org/10.1128/JVI.78.22.12665-12667.2004.
11. Johansson BE, Cox MM. 2011. Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines 10:1683-1695. http://dx.doi.org/10.1586/erv.11.130.
12. Marcelin G, Sandbulte MR, Webby RJ. 2012. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. RevMedVirol 22:267-279. http://dx.doi.org/10.1002/rmv.1713.
13. Schulman JL, Khakpour M, Kilbourne ED. 1968. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2:778-786.
14. Kilbourne ED, Laver WG, Schulman JL, Webster RG. 1968. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2:281-288.
15. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. 1974. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129:411-420. http://dx.doi.org/10.1093/infdis/129.4.411.
16. Rott R, Becht H, Orlich M. 1974. The significance of influenza virus neuraminidase in immunity. J Gen Virol 22:35-41. http://dx.doi.org/10.1099/0022-1317-22-1-35.
17. Johansson BE, Bucher DJ, Kilbourne ED. 1989. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 63:1239-1246.
18. Johansson BE, Grajower B, Kilbourne ED. 1993. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11:1037-1039. http://dx.doi.org/10.1016/0264-410X(93)90130-P.
19. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4:e59. http://dx.doi.org/10.1371/journal.pmed.0040059.
20. Webster RG, Reay PA, Laver WG. 1988. Protection against lethal influenza with neuraminidase. Virology 164:230-237. http://dx.doi.org/10.1016/0042-6822(88)90640-X.
21. Eichelberger MC, Wan H. 2015. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 386:275-299. http://dx.doi.org/10.1007/82_2014_398.
22. Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D. 2013. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 87:3053-3061. http://dx.doi.org/10.1128/JVI.02434-12.
23. Wohlbold TJ, Krammer F. 2014. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6:2465-2494. http://dx.doi.org/10.3390/v6062465.
24. Williams MS. 1993. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 37:253-262. http://dx.doi.org/10.1016/0378-1135(93)90027-5.
25. Hardy S, Eichelberger M, Griffiths E, Weir JP, Wood D, Alfonso C. 2011. Confronting the next pandemic-workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010. Influenza Other Respir Viruses 5:438-442. http://dx.doi.org/10.1111/j.1750-2659.2011.00250.x.
26. Murti KG, Webster RG. 1986. Distribution of hemagglutinin and neuraminidase on influenza virions as revealed by immunoelectron microscopy. Virology 149:36-43. http://dx.doi.org/10.1016/0042-6822(86)90084-X.
27. Kendal AP, Bozeman FM, Ennis FA. 1980. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect Immun 29:966-971.
28. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Jr, Ogra PL. 1987. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 138:3010-3013.
29. Johansson BE, Moran TM, Bona CA, Kilbourne ED. 1987. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J Immunol 139:2015-2019.
30. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED. 1987. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 139:2010-2014.
31. Johansson BE, Kilbourne ED. 1993. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 67:5721-5723.
32. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S. 2000. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214-3222. http://dx.doi.org/10.1016/S0264-410X(00)00149-3.
33. Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S. 1999. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 80:2559-2564.
34. Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Wang H, Zhang R, Chen Z. 2006. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidaseexpressing DNA in BALB/c mice. Biochem Biophys Res Commun 343:1124-1131. http://dx.doi.org/10.1016/j.bbrc.2006.03.088.
35. DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A. 2010. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 84:1489-1503. http://dx.doi.org/10.1128/JVI.01946-09.
36. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, Wan H, Eichelberger MC, Taubenberger JK. 2012. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432:39-44. http://dx.doi.org/10.1016/j.virol.2012.06.003.
37. Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW. 2012. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One 7:e42363. http://dx.doi.org/10.1371/journal.pone.0042363.
38. Deroo T, Jou WM, Fiers W. 1996. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14:561-569. http://dx.doi.org/10.1016/0264-410X(95)00157-V.
39. Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, van Amerongen G, Rimmelzwaan GF, de Haan CA, Osterhaus AD, Rottier PJ. 2010. Recombinant soluble, multimericHAandNAexhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J Virol 84:10366-10374. http://dx.doi.org/10.1128/JVI.01035-10.
40. Pavlova SP, Veits J, Keil GM, Mettenleiter TC, Fuchs W. 2009. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. Vaccine 27:773-785. http://dx.doi.org/10.1016/j.vaccine.2008.11.033.
41. Nayak B, Kumar S, DiNapoli JM, Paldurai A, Perez DR, Collins PL, Samal SK. 2010. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol 84:2408-2420. http://dx.doi.org/10.1128/JVI.02135-09.
42. Ramp K, Veits J, Deckers D, Rudolf M, Grund C, Mettenleiter TC, Romer-Oberdorfer A. 2011. Coexpression of avian influenza virus H5 and N1 by recombinant Newcastle disease virus and the impact on immune response in chickens. Avian Dis 55:413-421. http://dx.doi.org/10.1637/9652-011111-Reg.1.
43. Sylte MJ, Hubby B, Suarez DL. 2007. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 25:3763-3772. http://dx.doi.org/10.1016/j.vaccine.2007.02.011.
44. Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G. 2005. Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes. J Gen Virol 86:1455-1465. http://dx.doi.org/10.1099/vir.0.80788-0.
45. Sutter G, Ohlmann M, Erfle V. 1995. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett 371:9-12. http://dx.doi.org/10.1016/0014-5793(95)00843-X.
46. Halbherr SJ, Brostoff T, Tippenhauer M, Locher S, Berger Rentsch M, Zimmer G. 2013. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus. PLoS One 8:e66059. http://dx.doi.org/10.1371/journal.pone.0066059.
47. Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, Okamatsu M, Kida H. 2009. PB2 protein of a highly pathogenic avian influenza virus strain A/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol 83:1572-1578. http://dx.doi.org/10.1128/JVI.01879-08.
48. Soda K, Sakoda Y, Isoda N, Kajihara M, Haraguchi Y, Shibuya H, Yoshida H, Sasaki T, Sakamoto R, Saijo K, Hagiwara J, Kida H. 2008. Development of vaccine strains of H5 and H7 influenza viruses. Jpn J Vet Res 55:93-98. http://hdl.handle.net/2115/32369.
49. Ocana-Macchi M, Bel M, Guzylack-Piriou L, Ruggli N, Liniger M, McCullough KC, Sakoda Y, Isoda N, Matrosovich M, Summerfield A. 2009. Hemagglutinin-dependent tropism of H5N1 avian influenza virus for human endothelial cells. J Virol 83:12947-12955. http://dx.doi.org/10.1128/JVI.00468-09.
50. Brownie C, Statt J, Bauman P, Buczynski G, Skjolaas K, Lee D, Hotta J, Roth NJ. 2011. Estimating viral titres in solutions with low viral loads. Biologicals 39:224-230. http://dx.doi.org/10.1016/j.biologicals.2011.06.007.
51. Kalhoro NH, Veits J, Rautenschlein S, Zimmer G. 2009. A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27:1174-1183. http://dx.doi.org/10.1016/j.vaccine.2008.12.019.
52. Zimmer G, Locher S, Berger Rentsch M, Halbherr SJ. 2014. Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses. J Gen Virol 95:1634-1639. http://dx.doi.org/10.1099/vir.0.065201-0.
53. Berger Rentsch M, Zimmer G. 2011. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multispecies type I interferon. PLoS One 6:e25858. http://dx.doi.org/10.1371/journal.pone.0025858.
54. Hofmann MA, Renzullo S, Baumer A. 2008. Phylogenetic characterization of H5N1 highly pathogenic avian influenza viruses isolated in Switzerland in 2006. Virus Genes 37:407-413. http://dx.doi.org/10.1007/s11262-008-0285-2.
55. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, Perdue ML, Lohman K, Daum LT, Suarez DL. 2002. Development of a real-time reverse transcriptase PCR assay for typeAinfluenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 40:3256-3260. http://dx.doi.org/10.1128/JCM.40.9.3256-3260.2002.
56. Sylte MJ, Suarez DL. 2012. Vaccination and acute phase mediator production in chickens challenged with low pathogenic avian influenza virus; novel markers for vaccine efficacy? Vaccine 30:3097-3105. http://dx.doi.org/10.1016/j.vaccine.2012.02.055.
57. Webster RG, Brown LE, Laver WG. 1984. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 135:30-42. http://dx.doi.org/10.1016/0042-6822(84)90114-4.
58. Maupin KA, Liden D, Haab BB. 2012. The fine specificity of mannosebinding and galactose-binding lectins revealed using outlier motif analysis of glycan array data. Glycobiology 22:160-169. http://dx.doi.org/10.1093/glycob/cwr128.
59. Rogerieux F, Belaise M, Terzidis-Trabelsi H, Greffard A, Pilatte Y, Lambre CR. 1993. Determination of the sialic acid linkage specificity of sialidases using lectins in a solid phase assay. Anal Biochem 211:200-204. http://dx.doi.org/10.1006/abio.1993.1257.
60. von Itzstein M, Thomson R. 2009. Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol 189:111-154. http://dx.doi.org/10.1007/978-3-540-79086-0_5.
61. Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, Otto P, Zimmerman K, Vidugiris G, Machleidt T, Robers MB, Benink HA, Eggers CT, Slater MR, Meisenheimer PL, Klaubert DH, Fan F, Encell LP, Wood KV. 2012. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem Biol 7:1848-1857. http://dx.doi.org/10.1021/cb3002478.
62. Sultana I, Yang K, Getie-Kebtie M, Couzens L, Markoff L, Alterman M, Eichelberger MC. 2014. Stability of neuraminidase in inactivated influenza vaccines. Vaccine 32:2225-2230. http://dx.doi.org/10.1016/j.vaccine.2014.01.078.
63. Bucher DJ, Kilbourne ED. 1972. A 2 (N2) neuraminidase of the X-7 influenza virus recombinant: determination of molecular size and subunit composition of the active unit. J Virol 10:60-66.
64. von Grafenstein S, Wallnoefer HG, Kirchmair J, Fuchs JE, Huber RG, Schmidtke M, Sauerbrei A, Rollinger JM, Liedl KR. 2015. Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. J Biomol Struct Dyn 33:104-120. http://dx.doi.org/10.1080/07391102.2013.855142.
65. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44. http://dx.doi.org/10.1038/303041a0.
66. Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X. 2013. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 100:567-574. http://dx.doi.org/10.1016/j.antiviral.2013.09.018.
67. World Health Organization. 2002. WHOmanual on animal influenza diagnosis and surveillance. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf.
68. Hausmann J, Kretzschmar E, Garten W, Klenk HD. 1995. N1 neuraminidase of influenza virus A/FPV/Rostock/34 has haemadsorbing activity. J Gen Virol 76:1719-1728.
69. Uhlendorff J, Matrosovich T, Klenk HD, Matrosovich M. 2009. Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Arch Virol 154:945-957. http://dx.doi.org/10.1007/s00705-009-0393-x.
70. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. 2012. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. J Virol 86:13371-13383. http://dx.doi.org/10.1128/JVI.01426-12.
71. Hooper KA, Bloom JD. 2013. A mutant influenza virus that uses an n1 neuraminidase as the receptor-binding protein. J Virol 87:12531-12540. http://dx.doi.org/10.1128/JVI.01889-13.
72. Suzuki T, Takahashi T, Guo CT, Hidari KI, Miyamoto D, Goto H, Kawaoka Y, Suzuki Y. 2005. Sialidase activity of influenza A virus in an endocytic pathway enhances viral replication. J Virol 79:11705-11715. http://dx.doi.org/10.1128/JVI.79.18.11705-11715.2005.
73. Gerlach T, Kuhling L, Uhlendorff J, Laukemper V, Matrosovich T, Czudai-Matwich V, Schwalm F, Klenk HD, Matrosovich M. 2012. Characterization of the neuraminidase of the H1N1/09 pandemic influenza virus. Vaccine 30:7348-7352. http://dx.doi.org/10.1016/j.vaccine.2012.09.078.
74. Ohuchi M, Asaoka N, Sakai T, Ohuchi R. 2006. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 8:1287-1293. http://dx.doi.org/10.1016/j.micinf.2005.12.008.
75. Wagner R, Matrosovich M, Klenk HD. 2002. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12:159-166. http://dx.doi.org/10.1002/rmv.352.
76. Swayne DE, Lee CW, Spackman E. 2006. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathol 35:141-146. http://dx.doi.org/10.1080/03079450600597956.
77. Ewert DL, Barger BO, Eidson CS. 1979. Local antibody response in chickens: analysis of antibody synthesis to Newcastle disease virus by solid-phase radioimmunoassay and immunofluorescence with class-specific antibody for chicken immunoglobulins. Infect Immun 24:269-275.
78. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-4680. http://dx.doi.org/10.1093/nar/22.22.4673.
79. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599. http://dx.doi.org/10.1093/molbev/msm092.